Clinical Edge Journal Scan

Circulating miR-140 and serum leptin could help discriminate PsA from RA


 

Key clinical point: Increased expression levels of circulating microRNA (miRNA) like miR-140 and serum levels of few adipokines like leptin could serve as biomarkers for psoriatic arthritis (PsA) and could be particularly helpful in the differential diagnosis of peripheral PsA from other rheumatic diseases like rheumatoid arthritis (RA).

Major finding: MiR-140 and serum leptin levels were significantly higher in patients with PsA vs those with RA and healthy controls (HCs; both P < .001) and served as predictors of RA vs PsA (area under the receiver-operating characteristic curve, 0.91 and 0.83, respectively).

Study details: Findings are from a case-control study including 50 patients with peripheral PsA, 50 patients with RA, and 50 HCs.

Disclosures: No specific funding was received for this study. The authors declared no conflict of interests.

Source: Cheleschi S et al. Transl Res. 2021 Aug 8. doi: 10.1016/j.trsl.2021.08.001 .

Recommended Reading

Bimekizumab approved in Europe for psoriasis treatment
Psoriatic Arthritis ICYMI
PsA: Guselkumab demonstrates clinically meaningful and sustained improvement in fatigue
Psoriatic Arthritis ICYMI
Burden of psoriasis is mild in early PsA but impacts HRQoL
Psoriatic Arthritis ICYMI
Treating skin with biologics may reduce risk of developing PsA in patients with psoriasis
Psoriatic Arthritis ICYMI
JAK inhibitors safe and effective over placebo for PsA
Psoriatic Arthritis ICYMI
Secukinumab provides low radiographic progression over 2 years in patients with PsA
Psoriatic Arthritis ICYMI
Secukinumab effective for PsA, with high patient satisfaction in the real world
Psoriatic Arthritis ICYMI
Oligoarticular PsA similar to polyarticular PsA with few exceptions
Psoriatic Arthritis ICYMI
No clinically relevant increase in mortality in patients with PsA
Psoriatic Arthritis ICYMI
Identifying potential risks factors for PsA
Psoriatic Arthritis ICYMI